F-Prime Capital is the venture capital arm of Fidelity Investments, operating for more than 50 years with a structural advantage almost no other firm on this page shares: it invests without any pressure from outside fundraising, letting it back entrepreneurs on a genuinely long time horizon. That freedom has produced an unusually hands-on, company-formation-heavy model - F-Prime has co-created more than 30 companies from scratch, including Beam Therapeutics, Denali Therapeutics, and Innovent Biologics, working directly with academic researchers to spin science into standalone businesses rather than only backing existing startups. The firm invests stage-agnostically across healthcare (therapeutics, medtech, health IT) and technology (enterprise software, fintech, frontier tech), and now manages approximately $4.8 billion across a global portfolio of more than 300 companies.
Beam Therapeutics' 2020 Nasdaq IPO - President Stephen Knight personally co-founded the gene-editing company and has served on its board since 2017